Posted 03 November, 2023
Morphic Holding, Inc. appointed new CEO
CEO Change detected for ticker Nasdaq:MORF in a 8-K filed on 03 November, 2023.
As previously announced on September 26, 2023, Praveen P. Tipirneni, M.D., the Company's Chief Executive Officer and a member of the Company's board of directors (the "Board"), is taking a temporary medical leave of absence from his role as Chief Executive Officer. In connection with Dr. Tipirneni's leave of absence, effective November 1, 2023, the Board has appointed Bruce N. Rogers, Ph.D., the Company's President, as the Company's interim principal executive officer until Dr. Tipirneni's return.
$1.89B
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers. As previously announced on September 26, 2023, Praveen P. Tipirneni, M.D., the Company's Chief Executive Officer and a member of the Company's board of directors (the "Board"), is taking a temporary medical leave of absence from his role as Chief Executive Officer. In connection with Dr. Tipirneni's leave of absence, effective November 1, 2023, the Board has appointed Bruce N. Rogers, Ph.D., the Company's President, as the Company's interim principal executive officer until Dr. Tipirneni's return. Dr. Rogers continues to serve as the Company's President during this interim period.
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.